Xeris Biopharma Holdings, Inc. (XERS)
Xeris Biopharma: A Commercial Stage Pharma That May Be A Slow-Burn Buy Opportunity
Xeris Biopharma Holdings, Inc. achieved record 2024 revenues of $203M, up 24%, with robust growth across all three commercial products. 2025 revenue guidance of $255M–$275M implies 30% growth for XERS at midpoint, supporting a forward P/S ratio of ~3.4x and fair valuation. XP-8121, a once-weekly injectable levothyroxine, targets a $1B+ U.S. market and could be a future blockbuster pending Phase 3 trial initiation.
Xeris Biopharma Q2 Earnings Call Highlights
Xeris Biopharma NASDAQ: XERS reported second-quarter total revenue of $92.1 million, up 29% from a year earlier, as net product revenue increased 34% to $91 million. The company raised the low end of its full-year 2026 revenue outlook, now forecasting total revenue of $385 million to $390 million.
Xeris Biopharma Holdings, Inc. (XERS) Q2 2026 Earnings Call Transcript
Xeris Biopharma Holdings, Inc. (XERS) Q2 2026 Earnings Call Transcript
Compared to Estimates, Xeris Biopharma (XERS) Q2 Earnings: A Look at Key Metrics
The headline numbers for Xeris Biopharma (XERS) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Xeris Biopharma (XERS) Moves 6.8% Higher: Will This Strength Last?
Xeris Biopharma (XERS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Xeris Looks Ridiculously Cheap If Growth Forecasts Are Even Halfway Right
Xeris Biopharma has delivered another year of significant revenue growth, signaling a pivotal moment in its trajectory. XERS has reached an inflection point, indicating a shift in its business momentum and future prospects. The article highlights the company's expanding injectable medication portfolio as a driver for recent and anticipated growth.
Xeris Biopharma Q1 Earnings Call Highlights
Xeris Biopharma NASDAQ: XERS reported a sharp increase in first-quarter 2026 revenue and raised the low end of its full-year revenue outlook, citing strong demand for RECORLEV and continued execution across its commercial portfolio.
Xeris Biopharma Holdings, Inc. (XERS) Q1 2026 Earnings Call Transcript
Xeris Biopharma Holdings, Inc. (XERS) Q1 2026 Earnings Call Transcript
Xeris Biopharma (XERS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Xeris Biopharma (XERS) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Xeris Biopharma Holdings, Inc. (XERS) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Xeris Biopharma Holdings, Inc. (XERS) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Xeris Biopharma Holdings, Inc. (XERS) Q4 2025 Earnings Call Transcript
Xeris Biopharma Holdings, Inc. (XERS) Q4 2025 Earnings Call Transcript
Xeris Biopharma (XERS) Reports Q4 Earnings: What Key Metrics Have to Say
The headline numbers for Xeris Biopharma (XERS) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
